
|Videos|January 11, 2019
Benefits of PARP Inhibitor Use in Breast Cancer
Author(s)Jennifer Litton, MD
Advertisement
Jennifer Litton, MD, Breast Medical Oncologist, MD Anderson Cancer Center, describes how PARP inhibitors compare to standard of care in
Advertisement
Related Content
Advertisement





First-Line Treatment Choice and Altering Resistance in EGFR-Mutant NSCLC
Published: | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
2
FDA Approves Camizestrant for ESR1-Mutated Advanced Breast Cancer
3
Addressing Financial Toxicity: Team-Based Workflows in Oncology Care
4
Managing Daraxonrasib: Key Takeaways and Efficacy Insights for Oncology Nurses
5






















































